Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary, Hunan Dongting Pharmaceutical Co., Ltd., has obtained marketing registration approval from the National Medical Products Administration for its self-developed Levetiracetam sustained-release tablets for epilepsy. The drug is intended for use as an add-on therapy for partial-onset seizures in patients aged 12 or above. This approval is a significant step for the company in expanding its portfolio of pharmaceutical products.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.